Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ironwood Pharmaceuticals and Forest Laboratories have announced the availability of guanylate cyclase-C (GC-C) agonist, Linzess across the US pharmacies.
Subscribe to our email newsletter
The FDA approved, once-daily, oral product is indicated for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).
Linzess was designed to act locally in the intestine and to offer relief from the abdominal pain and constipation coupled with IBS-C and constipation and hard stools due to CIC.
The 290mcg dose of Linzess is recommended for IBS-C patients while 145mcg is recommended for CIC patients.
Linzess works by binding to GC-C receptor locally, resulting in increased intestinal fluid secretion and visceral pain reduction.